文献速递乳腺癌放疗中枢神经肿瘤放疗姑息放疗与转移瘤

乳腺癌放疗联合抗体药物偶联物安全性系统综述与荟萃分析

Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis.
PubMed 文献 · Radiother Oncol · 2026-09-30

该研究为ESTRO第二版国际共识推荐的一部分,系统检索并荟萃分析了29项研究、3817例接受ADC同步放疗的乳腺癌患者。结果显示严重放射性坏死、肺炎和皮肤毒性发生率低,颅外常规放疗联合T-DM1、T-DXd和SG总体安全,但颅内立体定向放疗尤其联合T-DM1时需警惕放射性坏死风险。

要点

  • 全组≥3级放射性坏死汇总发生率为5%,颅内立体定向放疗下≥3级治疗相关不良事件为8%。
  • ≥3级肺炎和≥3级皮肤副作用汇总发生率均为0%,提示肺与皮肤严重毒性罕见。
  • 颅外常规放疗期间使用T-DM1、T-DXd和SG可安全实施,但需维持常规安全监测。

核心结论

  • 多数临床场景下放疗可安全与ADC联合使用,严重并发症不常见。
  • 颅外常规放疗期间使用T-DM1、T-DXd和SG有证据支持,但需常规安全监测。
  • 颅内立体定向放疗仍需谨慎,尤其T-DM1患者放射性坏死风险 consistently 升高。
  • 当前数据未提示T-DXd或SG存在类似放射性坏死风险信号。

研究设计与样本

  • 该系统综述与荟萃分析为ESTRO指南委员会第二版国际共识推荐的一部分。
  • 检索PUBMED/MedLine、Embase和Cochrane数据库,纳入评估ADC联合放疗安全性的原始研究。
  • 最终纳入2014至2026年间发表的29项研究,共3817例至少接受一次放疗同步ADC治疗的患者。

主要发现

  • 报告该终点的所有研究中,≥3级放射性坏死汇总发生率为5%(95%CI:1-12%;I2=85.9%)。
  • 颅内放疗场景下,≥3级治疗相关不良事件汇总发生率为8%(95%CI:3-15%;I2=81.7%)。
  • T-DM1研究的亚组合并估计值最高,≥3级治疗相关不良事件发生率为13%(95%CI:1-34%)。
  • ≥3级肺炎汇总发生率为0%(95%CI:0-1%;12项研究),≥3级皮肤副作用汇总发生率为0%(95%CI:0-1%;13项研究)。

关键数值与推荐

  • 颅外常规放疗联合T-DM1、T-DXd和SG:推荐在维持常规安全监测的前提下使用。
  • 颅内立体定向放疗:尤其T-DM1患者需谨慎,因放射性坏死风险持续升高。
  • T-DXd和SG:当前数据未提示与T-DM1类似的放射性坏死风险信号。

临床怎么用

  • 对接受T-DM1、T-DXd或SG并同步颅外常规放疗的乳腺癌患者,可按常规安全监测实施放疗。
  • 对计划接受颅内立体定向放疗的患者,尤其使用T-DM1时,应充分评估放射性坏死风险并加强监测。
  • 使用T-DXd或SG并接受颅内立体定向放疗时,当前证据未显示类似T-DM1的放射性坏死风险信号,但仍需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The treatment landscape for breast cancer has undergone significant advancements in the recent years, with the introduction of several new anticancer agents, especially those belonging to the antibody-drug conjugates (ADCs) class. However, there exists a lack of comprehensive evidence regarding the safety profile of combining ADCs with radiation therapy (RT). Here we provide a summary of the available data on the safety of combining RT with ADCs in both early and metastatic breast cancer settings as part of updating European Society for Radiotherapy and Oncology (ESTRO) consensus. MATERIALS AND METHODS: This systematic review and meta-analysis project is part of the Second International Consensus Recommendations by the ESTRO Guidelines Committee on integrating RT with targeted treatments for breast cancer. A thorough literature search was conducted using the PUBMED/MedLine, Embase, and Cochrane databases to identify original studies focusing on the safety profile of combining ADCs with RT. RESULTS: After applying eligibility criteria, a total of 29 studies published between 2014 and 2026 were included, representing 3,817 patients who received at least one RT course concurrently to an ADC. The pooled grade ≥ 3 radiation necrosis rate across all studies reporting this endpoint was 5% (95% CI: 1-12%; I2 = 85.9%). In the intracranial RT setting, the pooled grade ≥ 3 treatment-related adverse event rate was 8% (95% CI: 3-15%; I2 = 81.7%), with T-DM1 studies showing the highest sub-total estimate of 13% (95% CI: 1-34%). Grade ≥ 3 pneumonitis was rare across all settings (pooled 0%; 95% CI: 0-1%; 12 studies), as well as grade ≥ 3 skin side effects (pooled 0%; 95% CI: 0-1%; 13 studies) were rare across all settings. CONCLUSION: RT can be safely delivered alongside ADCs therapy in most clinical settings, with severe complications occurring infrequently. The available evidence supports the use of conventional extracranial RT during treatment with T-DM1, T-DXd, and SG, provided that routine safety monitoring is maintained. In contrast, intracranial stereotactic RT remains the setting in which caution is warranted, particularly in patients receiving T-DM1, for whom an increased risk of radiation necrosis has been consistently reported. Current data does not suggest a similar risk signal for T-DXd or SG. Radiation necrosis; Stereotactic radiotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Visani L, Becherini C, Kubeczko M, et al. Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis. Radiother Oncol. 2026. PMID: 42815776. doi:10.1016/j.radonc.2026.111800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。